Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux. by Subbotina, Anna et al.
UC San Diego
UC San Diego Previously Published Works
Title
Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by 
sildenafil analogues that inhibit cellular cGMP efflux.
Permalink
https://escholarship.org/uc/item/6gd50420
Journal
The Journal of pharmacy and pharmacology, 69(6)
ISSN
0022-3573
Authors
Subbotina, Anna
Ravna, Aina W
Lysaa, Roy A
et al.
Publication Date
2017-06-01
DOI
10.1111/jphp.12693
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Inhibition of PDE5A1 guanosine cyclic monophosphate
(cGMP) hydrolysing activity by sildenafil analogues that
inhibit cellular cGMP efflux
Anna Subbotinaa, Aina W. Ravnaa, Roy A. Lysaaa, Ruben Abagyanb, Ryszard Bugnoc and
Georg Sagera
aExperimental and Clinical Pharmacology, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø – The Arctic University
of Norway, Tromsø, Norway, bSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California – San Diego, La Jolla, CA, USA
and cDepartment of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Keywords
guanosine cyclic monophosphate; inhibitors;
molecular modelling; PDE5; sildenafil
analogues
Correspondence
Georg Sager, Department of Medical
Biology, Faculty of Health Sciences,
University of Tromsø, N-9037 Tromsø,
Norway.
E-mail: georg.sager@uit.no
Received July 6, 2016
Accepted December 18, 2016
doi: 10.1111/jphp.12693
Abstract
Objectives To determine the ability of 11 sildenafil analogues to discriminate
between cyclic nucleotide phosphodiesterases (cnPDEs) and to characterise their
inhibitory potencies (Ki values) of PDE5A1-dependent guanosine cyclic
monophosphate (cGMP) hydrolysis.
Methods Sildenafil analogues were identified by virtual ligand screening (VLS)
and screened for their ability to inhibit adenosine cyclic monophosphate (cAMP)
hydrolysis by PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2, and
cGMP hydrolysis by PDE5A, PDE6C, PDE9A2 for a low (1 nM) and high concen-
tration (10 lM). Complete IC50 plots for all analogues were performed for
PDE5A-dependent cGMP hydrolysis. Docking studies and scoring were made
using the ICM molecular modelling software.
Key findings The analogues in a low concentration showed no or low inhibition
of PDE1A1, PDE1B1, PDE2A1, PDE3A, PDE10A1 and PDE10A2. In contrast,
PDE5A and PDE6C were markedly inhibited to a similar extent by the analogues
in a low concentration, whereas PDE9A2 was much less inhibited. The analogues
showed a relative narrow range of Ki values for PDE5A inhibition (1.2–14 nM).
The sildenafil molecule was docked in the structure of PDE5A1 co-crystallised
with sildenafil. All the analogues had similar binding poses as sildenafil.
Conclusions Sildenafil analogues that inhibit cellular cGMP efflux are potent
inhibitors of PDE5A and PDE6C.
Introduction
Cyclic nucleotide signalling plays an essential role in nor-
mal cell physiology and is impaired in many pathological
conditions, such as heart disease, pulmonary hypertension,
chronic obstructive pulmonary disease, obesity, diabetes
and cancer.[1] The family of human phosphodiesterases
(PDEs) comprises 11 main forms, from which PDEs 4, 7
and 8 are adenosine cyclic monophosphate (cAMP) selec-
tive; PDEs 5, 6 and 9 are guanosine cyclic monophosphate
(cGMP) selective; and PDEs 1, 2, 3, 10 and 11 hydrolyse
both cAMP and cGMP.[2] However, sildenafil raises cellular
cGMP levels by two mechanisms, reduction in cellular
efflux by ATP-binding cassette transporter subfamily C,
member 5 (ABCC5), previously termed multidrug resis-
tance-associated protein 5 (MRP5),[3] in addition to inhibi-
tion of PDE5 activity.[4]
Observations suggest that some binding site resemblance
exists between PDE5 and ABCC5. In addition to sildenafil,
other compounds with ability to inhibit PDE5 activity also
reduce cellular cGMP efflux, such as zaprinast,[3,5,6] dipyri-
damole,[5,6] vardenafil and tadalafil[6] and trequinsin.[3] In
contrast, non-selective PDE inhibitors, such as IBMX (3-iso-
butyl-1-methyl-xanthine),[6,7] caffeine and theophylline,[6]
have much lower affinity for the cGMP efflux pump.
The Ki ratio for sildenafil inhibition of cellular cGMP
efflux (ABCC5) and hydrolysis (PDE5) is approximately
1000 : 1. In an attempt to balance the action on ABCC5
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and PDE5 (Ki ratio reduction), we identified a series of 11
high-affinity cGMP transporter inhibitors by virtual ligand
screening (VLS).[8] Some of them, IN-01 and IN-02 with Ki
values of 75 and 65 nM, respectively, were clearly more
potent than sildenafil (Ki of 1200 nM) in their inhibition of
cGMP efflux.[8] The present work characterises their selec-
tivity towards other cnPDEs, their interaction with PDE5A
determined both by inhibition of cGMP hydrolysis, and
docking studies of the analogues into the enzyme-binding
site. The possibility of creating dual and balanced inhibitors
(of both PDE5 and ABCC5) by VLS (virtual ligand screen-
ing) represents the novelty of this study.
Materials and Methods
Sildenafil analogues
The sildenafil analogues (Table 1) were purchased from
Ambinter (Greenpharma SAS, Orleans, France) with excep-
tion of 4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)-N-[3-(1-methylpyrrolidin-2-yl)
pyridine-2-yl] benzenesulfonamide (I-03) which was
unavailable. Consequently, this compound was synthesised
at the Department of Medicinal Chemistry, Institute of
Pharmacology, Polish Academy of Sciences, Krakow,
Poland. The synthesis was achieved, using commercially
available 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl-1,6-dihy-
dro-7H-pyrazolo[4,3-d]-7-pyrimidinone (Sigma-Aldrich,
Schnelldorf, Germany), in three-step sequence following
procedures reported in the literature.[9] 2-Aminonicotine
used in the last step was prepared from ()-nicotine accord-
ing to the previously published procedure.[10]
Phosphodiesterase assay for screening of
sildenafil analogues
The screening was performed by BPS Bioscience Inc. (San
Diego, CA, USA) with the following materials: PDE assay
buffer (BPS), PDE binding agent (BPS), PDE binding agent
diluent for cAMP (BPS), PDE binding agent diluent for
cGMP (BPS), Bay 60-7550 was purchased from Cayman
Chemicals (Ann Arbor, MI, USA), and cilostamide, silde-
nafil citrate and papaverine were purchased from Axxora
(San Diego, CA, USA). Bay 73-6691 was obtained from
Sigma-Aldrich (St. Louis, MO, USA). The assays comprised
10 lM and 1 nM dilutions of the test compound in assay
buffer (10% DMSO concentration), and 5 ll of the dilution
was added to a 50 ll reaction so that the final concentration
of DMSO is 1% in all of reactions. The enzymatic reactions
were conducted at room temperature for 60 min in a 50 ll
mixture containing PDE assay buffer, 100 nM FAM-cAMP,
or 100 nM FAM-cGMP, a cnPDE enzyme and the test com-
pound. Bay 60-7550 (10 lM) was used as a reference
compound for PDE1A1, PDE1B, PDE1C and PDE2A1 with
respective inhibition of 98%, 97%, 98% and 99%. Cilosta-
mide (10 lM) was used for PDE3A and PDE3B and inhib-
ited 99% and 99% of activity. The reference substance for
PDE5 and PDE6C was sildenafil (1 lM) and inhibited both
enzymes with 99%. The reference substance for PDE9A was
Bay73-6691 (10 lM) which gave an inhibition of 99%.
Papaverine (10 lM) was employed for PDE10A1 and
PDE10A2 and inhibited 99% of activity. After the enzymatic
reaction, 100 ll of a binding solution (1 : 100 dilution of
the binding agent with the binding agent diluent) was
added to each reaction, and the reaction was performed at
room temperature for 60 min. Fluorescence intensity was
measured at an excitation of 485 nm and an emission of
528 nm using a Tecan Infinite M1000 microplate reader.
PDE activity assays were performed in duplicate at each
concentration. Fluorescence intensity was converted to flu-
orescence polarisation using the Tecan Magellan6 software.
The fluorescence polarisation data were analysed using the
computer software, GraphPad Prism (GraphPad Software,
San Diego, CA, USA). The fluorescence polarisation (FPt)
in absence of the compound in each data set was defined as
100% activity. In the absence of cnPDE and the compound,
the value of fluorescent polarisation (FPb) in each data set
was defined as 0% activity. The per cent activity in the
presence of the compound was calculated according
to the following equation: % activity = (FP  FPb)/
(FPt  FPb) 9 100%, where FP = the fluorescence polari-
sation in the presence of the compound.
IC50 assay for PDE5A1 characterisation
Phosphodiesterase 5A1 human, recombinant, expressed in
Sf9 cells, Supelco Discovery SPE (1 ml) with DSC-SAX
(100 mg/ml), unlabelled cGMP, crotalus atrox venom and
bovine serum albumin were purchased from Sigma-Aldrich.
[3H]-cGMP (sp. act 1 mCi/mmol) was obtained from Perki-
nElmer Inc (Boston, MA, USA). The Km values of the
PDE5A1 cGMP hydrolysis were determined using mixtures
of [3H]-cGMP and non-labelled cGMP to achieve total
cGMP concentrations from 0.1 to 10 lM. To obtain IC50 val-
ues, seven concentrations (0.01 nM–10 lM) of each inhibitor
were incubated with 5 lM [3H]-cGMP/unlabelled cGMP.
The reaction mixture comprised 20 mM Tris–HCl (pH 7.5),
0.3 mg/ml BSA, 1.5 mM dithiothreitol and 3 mM MgCl2.
Incubation time was 10 min at 30 °C. In all studies, less than
10% of added [3H]-cGMP was hydrolysed to [3H]-GMP
during the reaction. The reaction was terminated by transfer-
ring the reactant to a water bath (100 °C for 1 min) and
cooled on ice (1–2 min). [3H]-GMP was hydrolysed to
[3H]-guanosine by adding 2.5 ll 10 mg/ml crotalus atrox
snake venom which contains a potent 50-nucleotidase.[11]
The mixture was incubated for 10 min at 30 °C and then
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Table 1 Inhibitors (sildenafil analogues), IUPAC-names, molecular structure and PubChem CID
Inhibitor IUPAC name Molecular structure PubChem CID
Sildenafil 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-
methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidine-7-one
N
N
O
N
N
O S
O
O
N N
5212
IN-01 5-[[3-(3-tert-butyl-1-methyl-7-oxo-4H-pyrazolo[4, 3-d]
pyrimidin-5-yl)-4-ethoxyphenyl]sulfonylamino]-2-
hydroxybenzoic acid N
N
N
S
N
N
O
O
O
O
O
O
O
1598490
IN-02 5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)phenyl]sulfonylamino]-2-
hydroxybenzoic acid
N
S
N
N
NN
O
O
O
O
O
O
O
1899750
IN-03 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4, 3-d]
pyrimidine-5-yl)-N-[3-(1-methylpyrrolidin-2-yl)pyridine-2-yl]
benzenesulfonamide
S
N
N N
N N N
O
O
N
O
O
4921527
IN-04 4-Ethoxy-N,N-diethyl-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)benzenesulfonamide
N
S
N N
N N
O
O
O
O
1899174
IN-05 4-Ethoxy-N-methyl-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)benzenesulfonamide
N
N N
N
S
O
O
O
N
O
1896380
IN-06 4-Ethoxy-N-(2-hydroxyethyl)-3-(1-methyl-7-oxo-3-propyl-4H-
pyrazolo[4, 3-d]pyrimidine-5-yl)benzenesulfonamide
N
N
N
N
S
O
O
O
N
O
O
1900265
IN-07 4-Ethoxy-N-(2-Hydroxyethyl)-N-Methyl-3-(1-Methyl-7-Oxo-3-
Propyl-4H- Pyrazolo[4,3-D]Pyrimidine-5-Yl)Benzenesulfonamide N
S
N
N
NN
O
O
O
O
O
1896597
IN-08 5-[5-(azepan-1-ylsulfonyl)-2-ethoxyphenyl]-1-methyl-3-propyl-
4H-pyrazolo [4,3-d]pyrimidine-7-one
S
N
N
N
N N
O
O
O
O
1897952
IN-09 5-(2-ethoxy-5-piperidin-1-ylsulfonylphenyl)-1-methyl-3-propyl-
4H- pyrazolo[4,3-d]pyrimidine-7-one
S
N
N
N
N N
O
O
O
O
1896867
IN-10 4-Ethoxy-N,N-dimethyl-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)benzenesulfonamide
N
S
N
N
N N
O
O
O
O
1902581
IN-11 N-Benzyl-4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo
[4, 3-d]pyrimidine-5-yl)benzenesulfonamide
N
N
S
N
N N
O
O
O
O
1896826
The compounds were identified by virtual ligand screening (VLS).[8]
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diluted in 250 ll 10 mM Tris/8.2 mM propionic acid (pH
7.5). The samples were applied on a preconditioned/equili-
brated DSC-SAX column to separate [3H]-guanosine from
[3H]-GMP. The columns were washed with 100 ll 10 mM
Tris/8.2 mM propionic acid buffer (pH 7.5) five times. The
eluate (400 ll) was transferred to a scintillation vial contain-
ing 10-ml scintillation cocktail (Ultima Gold XR; Packard,
Groningen, the Netherlands), and radioactivity was quanti-
fied in a Packard 1900 TR Liquid Scintillation analyser.
Data analysis and statistics
Values for Km and IC50 were obtained according to
Chou,[12] and Ki values were calculated according to Cheng
and Prusoff.[13] The descriptive statistics is presented as
mean value  SE in text, tables and figures. Kruskal-Wallis
test (nonparametric ANOVA) with Dunn’s multiple com-
parisons post-test was used to compare the Ki values for the
analogues with that of sildenafil (InStat, ver. 3.10 for Win-
dows; GraphPad Software).
Molecular modelling
Docking studies and scoring were performed using the
ICM molecular modelling software (Molsoft LLC, San
Diego, CA, USA).[14] The crystal structure of PDE5A1[15]
in complex with sildenafil (PDB ID: 2H42) with the reso-
lution 2.3 A was converted to an ICM object, and recep-
tor maps were calculated based on the pocket defined by
position of co-crystallised sildenafil in the crystal struc-
ture. Ligands were prepared in the ICM ligand editor
and converted to 3D when setting up the ligand during
the docking session. Charges were also assigned in this
step. The ligands were modelled using the ICM molecule
editor and docked into PDE5 using interactive docking.
Tautomer sampling was performed, as sildenafil may
exist in three tautomeric forms. The docking poses were
scored by the ICM scoring function. The scoring function
gives a score optimised to rank order the docking hits by
their binding affinity.[16] The lower the ICM score, the
higher the chance the ligand has a high affinity to the
drug target.
Results
Sildenafil analogues and cyclic nucleotide
phosphodiesterase selectivity
The sildenafil analogues (Table 1) obtained for inhibition
studies of cGMP efflux[8] were screened for their ability to
Table 2 The inhibitors (IN-01–IN-11) listed in Table 1 were screened for their inhibitory activity on a panel of phosphodiesterase (PDE) family
members as described in Methods
PDE1A1 PDE1B PDE1C PDE2A1 PDE3A PDE3B PD5A PDE6C PDE9A2 PDE10A1 PDE10A2
IN-01 93  1.4 100  2.8 90  0.7 97  0 101  3.5 102  2.1 41  0.7 33  1.4 95  5.7 99  0.7 99  0
30  1.4 41  2.8 26  0.7 33  0.7 46  2.1 40  0 4.0  1.4 11  1.4 7.0  2.8 39  1.4 30  1.4
IN-02 94  2.1 96  2.1 97  1.4 97  0.7 98  0 100  4.2 35  1.4 45  2.8 92  0 99  0.7 97  2.1
44  0 51  1.4 39  1.4 45  1.4 65  1.4 50  2.1 15  2.1 11  2.8 17  1.4 57  0 43  0
IN-03 96  2.8 98  1.4 98  2.1 95  0 97  0 98  0 93  0.7 69  0 97  5.7 93  0 99  0.7
2.0  0 6.0  0.7 1.0  0 29  1.4 51  0.7 62  1.4 1.0  0 3.5  0.7 29  2.8 2.0  2.8 7  0
IN-04 95  3.5 96  0.7 99  0.7 99  0 98  2.1 102  0 49  0.7 49  4.9 95  0 94  2.8 98  1.4
10  1.4 16  0 0  1.4 46  1.4 50  0.7 65  0.7 1.0  0 4.5  2.1 29  5.7 25  2.1 31  0
IN-05 94  0 99  2.1 99  0.7 97  1.4 96  0.7 99  1.4 94  3.5 81  2.8 97  3.5 99  0.7 94  4.2
15  2.1 23  2.1 0.5  0.7 50  1.4 79  0 83  0.7 1.5  0.7 2.5  2.1 37  3.5 46  0.7 53  0
IN-06 95  0.7 98  3.5 99  0.7 99  1.4 92  0.7 97  1.4 98  2.1 89  2.1 100  3.5 95  4.9 96  0
2.0  2.8 24  2.8 3.0  1.4 57  2.1 78  0.7 87  2.1 3.5  3.5 6.0  2.8 48  0 52  0.7 63  0
IN-07 96  2.0 95  3.5 98  0 97  1.4 95  2.1 98  0.7 93  2.1 74  2.1 101  1.4 92  2.8 97  0.7
12  0 29  1.4 1.0  1.4 60  2.1 73  0.5 83  0.7 2.5  0.7 6.5  2.1 28  3.5 57  0.7 61  1.4
IN-08 94  0.7 98  2.1 97  0.7 96  1.4 101  2.8 100  0 37  2.8 44  0.7 98  5.7 90  2.8 99  0.7
16  3.5 22  2.1 2.0  0.7 77  0 78  3.5 84  0.7 1.5  0.7 1.0  0 56  1.4 60  2.8 69  2.1
IN-09 92  0.7 98  2.1 97  2.1 99  2.1 95  2.8 98  1.4 59  4.2 66  0 100  0.7 98  1.4 97  0.7
12  1.4 28  0.7 1.0  0 79  2.1 74  0.7 88  2.8 1.5  0.7 1.5  0.7 67  1.4 60  0.7 66  2.8
IN-10 97  1.4 99  2.1 97  0.7 96  0.7 98  2.1 100  0.7 101  4.2 97  0 95  1.4 94  0.7 101  0.7
11  0 31  0 3.0  0.7 55  0.7 69  3.5 81  2.1 1.0  0 6.0  1.4 33  4.9 56  4.2 60  0
IN-11 99  0.7 94  0.7 97  1.4 99  1.4 96  2.1 99  0.7 90  1.4 60  3.5 98  0.7 97  2.8 98  2.8
11  0.7 28  2.8 5.0  0 34  0.7 83  2.8 91  0.7 4.0  1.4 5.0  1.4 78  0.7 69  3.5 89  2.8
They were tested in duplicates for two concentrations (1 nM/10 lM). FAM-cAMP (100 nM) was used as substrate for PDE1s, PDE2A1, PDE3s and
PDE10s, whereas FAM-cGMP (100 nM) was used for PDE5A, PDE6C and PDE9A2. PDE5A was also tested with 1 nM and 10 lM sildenafil (as a pos-
itive control) and reduced the cGMP hydrolysis to 58  1.4% and 1  0% of control, respectively. Results (mean  SE) are presented as % of
control representing two time-independent experiments each in duplicate.
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inhibit PDE5A and other members of the cnPDE family
(Table 2). As described in methods, the screening was per-
formed with a high and low concentration of the com-
pounds. For the cGMP hydrolysing enzymes, the following
order of potency existed; for PDE5A (1 nM inhibitor): IN-
02 = IN-08 ≥ IN-01 > IN-04 > IN-09 > IN-11 ≥ IN-03 =
IN-07 = IN-05 ≥ IN-06 = IN-10. The respective order for
PDE6C (1 nM inhibitor) was IN-01 > IN-08 = IN-
02 ≥ IN-04 > IN-11 > IN-09 ≥ IN-03 > IN-07 > IN-05 >
IN-06 > IN-10. The inhibitors had low affinity for PDE9A2
with a test concentration of 1 nM. The members of PDE-
subfamilies tested for cAMP hydrolysis showed negligible
inhibition with 1 nM. Increasing the test concentration to
10 lM gave markedly inhibition of some of the other
cnPDEs, including the PDE1, PDE2A1 and the PDE3 (sub-
)families. Finally, some of the analogues, in the highest
tested concentration, gave virtually complete inhibition of
PDE10A1 and PDEA2.
Characterisation of PDE5A1 inhibition by
sildenafil analogues
The characteristics (IC50/Ki values) of the 11 sildenafil
analogues were assessed by full concentration–inhibition
curves for their ability to inhibit PDE5A1-mediated
cGMP hydrolysis. The Km value of PDE5A1-mediated
cGMP hydrolysis was 1.7  0.4 lM. Sildenafil was
employed as reference compound for the inhibitors. A Ki
value of 3.3  0.9 nM was obtained for sildenafil under
the present experimental conditions. All analogues inhib-
ited the PDE5A1-dependent cGMP hydrolysis in a con-
centration-dependent manner. Figure 1 shows IC50 curves
for the analogues with sildenafil as reference substance.
Table 3 shows both IC50 and Ki values. Three analogues
were more potent than the rest (Figure 1, panel a), IN-
03, IN-08 and IN-09 with Ki values from 1.2 to 1.9 nM
(Table 3). Figure 1 (panel b) shows the second group
Figure 1 The sildenafil analogues were tested for their inhibition of PDE5A-mediated cGMP hydrolysis as described in methods. The experimen-
tal points represent mean  SE (n = 6). Sildenafil was used as reference substance. Panel a: sildenafil (●), IN-03 (▲), IN-08 (9) and IN-09 (■).
Panel b: sildenafil (●), IN-01 (▲), IN-02 (9) and IN-04 (■). Panel c: sildenafil (●), IN-05 (▲), IN-11 (9), panel d: sildenafil (●), IN-06 (▲), IN-07 (9)
and IN-10 (■).
© 2017 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
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(IN-01, IN-02 and IN-04) with intermediate affinities (Ki
values from 2.6 to 3.0 nM), virtually identical with that
of sildenafil (Table 3). The third group (Figure 1, panel
c) comprised IN-05 and IN-11 (Ki-values were 7.8 and
9.8 nM). The last group (Figure 1, panel d) with the low-
est affinities (Ki value range was 12–14 nM) consisted of
IN-06, IN-07 and IN-10. The inhibition curves of silde-
nafil were shifted from the right (Figure 1, panel a) to
the left (Figure 1, panel d). Statistical analysis with
Kruskal-Wallis test (nonparametric ANOVA) gave a
P value < 0.0001, considered extremely significant. How-
ever, the Dunn’s multiple comparisons post-test showed
that only IN-06 and IN-10 had Ki-values significantly dif-
ferent from that of sildenafil (Table 3).
Docking of novel sildenafil analogues to the
crystal structure of PDE5A1 catalytic domain
To assess the accuracy of ICM docking procedure, the
sildenafil molecule was docked in the structure of
PDE5A1 co-crystallised with sildenafil. Self-docking
showed that it occupied spatially the same place as silde-
nafil from crystal structure (Figure 2, panel a). All the
analogues had similar binding poses as sildenafil (Fig-
ure 2, panel b). The heterocyclic ring system of the silde-
nafil-like compounds spatially occupied the same
position as in the crystal structure of PDE5A1 with silde-
nafil. Additionally, the salicylic acid moiety of the com-
pounds IN-01 and IN-02 formed hydrogen bonds with
Arg667 and Asn661 (Figure 2, panel c).
Discussion
Sildenafil has become a reference substance for inhibitors
of PDE5.[17] However, other molecular targets for sildenafil
have been discovered such as ABC-transporters. Sildenafil
interacts with ABCB1 (P-glycoprotein) and ABCG2 (breast
cancer resistance protein),[18] ABCC4 (MRP4),[19–21]
ABCC5 (MRP5)[3,5,19] and ABCC10 (MRP7).[22,23] It was
not surprising that the sildenafil analogues identified with
VLS[8] inhibited activity of ABCC5[8] and ABCC4.[21] These
analogues were characterised in this study to decide
whether they were able to distinguish between the various
cnPDEs and to determine their affinities for PDE5.
The properties of cnPDEs have been extensively reviewed
by Conti and Beavo.[2] Some PDEs hydrolyse both cAMP
and cGMP at low substrate levels (PDEs 1, 2, 3, 10 and 11).
The present results showed that members of PDE family 1,
2, 3 and 10 were not, or only to a minor extent, inhibited
when analogue concentrations were 1 nM. Increasing the
concentrations to 10 lM caused a clear inhibition. Some
PDEs selectively recognise and hydrolyse cGMP (PDEs 5, 6
and 9). In this study, the same analogues showed equipo-
tent inhibition of PDE5A and PDE6C. In agreement with
this, PDE6 binds sildenafil with similar affinity as PDE5.[24]
On the other hand, the inhibitory potency of PDE9A was
much lower.
The screening was succeeded by a thorough characterisa-
tion of the inhibitors on PDE5A-mediated cGMP hydroly-
sis activity. The two different methods employed for
screening and PDE5A characterisation gave similar but not
identical results. The methods employed for detailed stud-
ies on PDE5A were established 4–5 decades ago[25] but is
still in use after continuous refinements.[26] The Km value
of PDE5A cGMP hydrolysis was 1.7 lM, virtually identical
to that reported (2 lM) by Francis et al.[27] Furthermore,
the Ki value (3.3 nM) obtained here for sildenafil inhibition
of PDE5A is in close agreement with that (4 nM) consid-
ered as typical.[27] The 11 sildenafil analogues were able to
inhibit cGMP hydrolysis by PDE5 within a relative narrow
range of Ki values (1.2–14 nM). Only two of the analogues
had Ki-values statistically different from that of sildenafil.
This shows that VLS, at least in our hands, is a robust
method to predict drug analogues.[8] The molecular mod-
elling employed in this study emphasises the potential of
this technology. The inhibitors were recognised by the same
binding site as sildenafil and showed an overlapping inter-
action. The pyrazolopyrimidine group stacked against
phenylalanine-820 and the compounds formed two hydro-
gen bonds with glutamine-817, previously shown to play
key role in PDE5 inhibitor binding.[28]
The aim of our work was to identify and characterise
sildenafil-like inhibitors with a balanced effect on cGMP
hydrolysis and cGMP efflux. In our experimental set-ups,
Table 3 IC50 and Ki values of PDE5A cGMP hydrolysis for sildenafil
and its analogues
Inhibitor IC50 (nM) Ki (nM)
Sildenafil 10.3  2.8 3.3  0.9
IN-01 9.7  0.02 3.0  0.01ns
IN-02 8.2  3.7 2.6  1.2ns
IN-03 4.5  1.3 1.4  0.4ns
IN-04 9.2  0.7 2.9  0.2ns
IN-05 24.8  1.2 7.8  0.4ns
IN-06 44.3  4.9 14.0  1.6*
IN-07 37.9  6.8 12.0  2.2ns
IN-08 3.9  0.7 1.2  0.2ns
IN-09 6.0  1.2 1.9  0.4*
IN-10 43.4  2.3 13.7  0.7*
IN-11 30.5  1.7 9.6  0.6ns
IC50 curves were obtained for inhibitor concentrations between
0.1 nM and 10 lM, and the IC50 value were calculated (given as
mean  SE, n = 6) as described by Chou[12] and transformed to Ki
values (given as mean  SE) according to Cheng and Prusoff.[13] The
results were obtained from three time-independent series. The Ki val-
ues of analogues were compared statistically with that of sildenafil.
Kruskal-Wallis test with Dunn’s multiple comparisons post-test;
ns = p > 0.05, * = p < 0.05.
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we found virtually identical values Km values for PDE5
cGMP hydrolysis (1.7 lM) in the present work and Km val-
ues for high-affinity cGMP transport as reported in previ-
ous studies: 2.4,[7] 2.2[8] and 2.6 lM.[21] On the other hand,
the Ki values of sildenafil inhibition of PDE5A1 cGMP
hydrolysis and high-affinity cGMP efflux are extremely dif-
ferent. Previously we have reported Ki values of 1.2–
3.6 lM[5,8] for the active cellular extrusion of cGMP. This
(a)
(b)
(c)
Figure 2 Docking of sildenafil and sildenafil analogues into the crystal structure of PDE5A. Panel a: Location of sildenafil (red) after self-docking
and that of sildenafil (black) co-crystallised with PDE5. Panel b: Location and poses of the 11 sildenafil analogues in the sildenafil binding site.
Panel c: Location of the salicylic acid moiety of the compounds IN-01 and 1N-02 [Colour figure can be viewed at wileyonlinelibrary.com].
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means a Ki ratio (transport/hydrolysis) of approximately
1000 : 1. It is intriguing that the Ki ratios were clearly
lower for some of the sildenafil analogues, being 25 : 1
for both IN-01 and IN-02, and 100 : 1 for IN-03. This
demonstrates that single molecules may balance action
on these two different molecular targets and thereby
enhancing the effect of intracellular cGMP. However, the
ABC-transporters are multipurpose pumps (‘vacuum
cleaners’) with the ability to remove excess of potential
harmful endo- and exobiotics. Development of dual and
balanced inhibitors should not completely block this vital
cellular function.
Conclusions
Virtual ligand screening was employed to identify sildenafil
analogues. In previous studies, some of these compounds
reduced cellular efflux of cGMP. In the present work, several
of the analogues were more potent, equipotent or less potent
than sildenafil in their inhibition of PDE5A-mediated cGMP
hydrolysis. Taken together, these results demonstrate that it is
possible to design inhibitors with dual and balanced action.
Declarations
Conflict of interest
The Authors declare that they have no conflict of interests
to disclose.
Acknowledgements
The grants from the Norwegian Cancer Association, Aakre
Foundation for Cancer Research, Raagholt Foundation for
Health Research and the statutory funds of the Institute of
Pharmacology (Polish Academy of Sciences) are acknowl-
edged.
References
1. Das A et al. PDE5 inhibitors as therapeu-
tics for heart disease, diabetes and cancer.
Pharmacol Ther 2015; 147: 12–21.
2. Conti M, Beavo J. Biochemistry and
physiology of cyclic nucleotide phos-
phodiesterases: essential components
in cyclic nucleotide signaling. Annu
Rev Biochem 2007; 76: 481–511.
3. Jedlitschky G et al. The multidrug
resistance protein 5 functions as an
ATP-dependent export pump for cyc-
lic nucleotides. J Biol Chem 2000; 275:
30069–30074.
4. Corbin JD et al. Phosphodiesterase
type 5 as a pharmacologic target in
erectile dysfunction. Urology 2002; 60:
4–11.
5. Sundkvist E et al. Pharmacological
characterization of the ATP-depen-
dent low K(m) guanosine 30,50-cyclic
monophosphate (cGMP) transporter
in human erythrocytes. Biochem Phar-
macol 2002; 63: 945–949.
6. Aronsen L et al. Modulation of
high affinity ATP-dependent cyclic
nucleotide transporters by specific
and non-specific cyclic nucleotide
phosphodiesterase inhibitors. Eur J
Pharmacol 2014; 745: 249–253.
7. Schultz C et al. Cyclic AMP stimu-
lates the cyclic GMP egression pump
in human erythrocytes: effects of pro-
benecid, verapamil, progesterone,
theophylline, IBMX, forskolin, and
cyclic AMP on cyclic GMP uptake
and association to inside-out vesicles.
Biochemistry 1998; 37: 1161–1166.
8. Sager G et al. Novel cGMP efflux
inhibitors – identified by virtual
ligand screening (VLS) and confirmed
by experimental studies. J Med Chem
2012; 55: 3049–3057.
9. Flores Toque HA et al. Synthesis and
pharmacological evaluations of silde-
nafil analogues for treatment of erec-
tile dysfunction. J Med Chem 2008;
51: 2807–2815.
10. Latli B et al. Novel and potent 6-
chloro-3-pyridinyl ligands for the
alpha4beta2 neuronal nicotinic acetyl-
choline receptor. J Med Chem 1999;
42: 2227–2234.
11. Butcher RW, Sutherland EW. Adeno-
sine 30,50-phosphate in biological
materials. I. Purification and proper-
ties of cyclic 30,50-nucleotide phospho-
diesterase and use of this enzyme to
characterize adenosine 30,50-phosphate
in human urine. J Biol Chem 1962;
237: 1244–1250.
12. Chou TC. Derivation and properties
of Michaelis-Menten type and Hill
type equations for reference ligands. J
Theor Biol 1976; 39: 253–276.
13. Cheng YC, Prusoff WH. Relationship
between the inhibition constant (KI)
and the concentration of inhibitor
which causes 50 per cent inhibition
(IC50) of an enzymatic reaction.
Biochem Pharmacol 1973; 22: 3099–
3108.
14. Abagyan R et al. ICM – a new
method for protein modeling and
design. Applications to docking and
structure prediction from the dis-
torted native conformation. J Comput
Chem 1994; 15: 488–506.
15. Wang H et al. Multiple conformations
of phosphodiesterase-5: implications
for enzyme function and drug develop-
ment. J Biol Chem 2006; 281: 21469–
21479.
16. Totrov M, Abagyan R. Derivation of
sensitive discrimination potential
for virtual ligand screening. In:
Istrail S, Pevzner P, Waterman M,
eds. Proceedings of the Third Annual
International Conference on Computa-
tional Molecular Biology. Lyon,
France: ACM (New York), 1999:
312–320.
17. Francis SH et al. Inhibition of cyclic
nucleotide phosphodiesterases by
methylxanthines and related com-
pounds. In: Fredholm BB, ed. Handb
Exp Pharmacol. Berlin Heidelberg:
Springer Verlag, 2011: 93–133.
© 2017 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
on behalf of Royal Pharmaceutical Society, 69 (2017), pp. 675–683
682
Sildenafil analogues as inhibitors of PDE5A Anna Subbotina et al.
18. Shi Z et al. Sildenafil reverses ABCB1-
and ABCG2-mediated chemotherapeutic
drug resistance. Cancer Res 2011; 71:
3029–3041.
19. Chen ZS et al. Analysis of methotrexate
and folate transport by multidrug resis-
tance protein 4 (ABCC4): MRP4 is a
component of the methotrexate efflux
system. Cancer Res 2002; 62: 3144–
3150.
20. Reid G et al. Characterization of the
transport of nucleoside analog drugs
by the human multidrug resistance
proteins MRP4 and MRP5. Mol Phar-
macol 2003; 63: 1094–1103.
21. Orvoll E et al. Misoprostol and the
sildenafil analog (PHAR-0099048)
modulate cellular efflux of cAMP and
cGMP differently. Pharmacol Pharm
2013; 4: 104–109.
22. Chen ZS et al. Characterization of the
transport properties of human multidrug
resistance protein 7 (MRP7, ABCC10).
Mol Pharmacol 2003; 63: 351–358.
23. Chen JJ et al. PDE5 inhibitors, sildenafil
and vardenafil, reverse multidrug resis-
tance by inhibiting the efflux function
of multidrug resistance protein 7 (ATP-
binding Cassette C10) transporter. Can-
cer Sci 2012; 103: 1531–1537.
24. Zhang X et al. Efficacy and selectivity
of phosphodiesterase-targeted drugs in
inhibiting photoreceptor phosphodi-
esterase (PDE6) in retinal photorecep-
tors. Invest Ophthalmol Vis Sci 2005;
46: 3060–3066.
25. Beavo JA et al.Hydrolysis of cyclic guano-
sine and adenosine 30,50-monophosphates
by rat and bovine tissues. J Biol Chem
1970; 245: 5649–5655.
26. Sonnenburg WK et al. Identification,
quantitation, and cellular localization
of PDE1 calmodulin-stimulated cyclic
nucleotide phosphodiesterases. Meth-
ods 1998; 14: 3–19.
27. Francis SH et al. Cyclic nucleotide
phosphodiesterases: relating structure
and function. Prog Nucleic Acid Res
Mol Biol 2001; 65: 1–52.
28. Zoraghi R et al. Phosphodiesterase-5
Gln817 is critical for cGMP, vardenafil,
or sildenafil affinity: its orientation
impacts cGMP but not cAMP affinity. J
Biol Chem 2006; 281: 5553–5558.
© 2017 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
on behalf of Royal Pharmaceutical Society, 69 (2017), pp. 675–683
683
Anna Subbotina et al. Sildenafil analogues as inhibitors of PDE5A
